KEYCORP DECLARES QUARTERLY CASH DIVIDEND ON COMMON SHARES AND PREFERRED STOCKS; SETS ANNUAL MEETING DATE

Rhea-AI Summary

Rigel Pharmaceuticals (Nasdaq: RIGL) announced the first patient enrollment in a Phase 1b/2 trial at MD Anderson testing oral or IV decitabine and venetoclax combined with REZLIDHIA (olutasidenib) for mIDH1 acute myeloid leukemia (AML) on Jan 15, 2026.

The Phase 1b portion will assess safety/tolerability and recommended Phase 2 dose; the Phase 2 will enroll 60 patients (30 newly diagnosed, 30 relapsed/refractory) to evaluate complete remission rate. REZLIDHIA is FDA‑indicated for relapsed/refractory mIDH1 AML. The release includes safety data: differentiation syndrome and hepatotoxicity incidence and management guidance.

Positive

• First patient enrolled in the Phase 1b/2 triplet trial
• Phase 2 size set at 60 patients (30 newly diagnosed, 30 R/R)
• REZLIDHIA has an FDA indication for R/R mIDH1 AML

Negative

• Differentiation syndrome occurred in 16% of treated patients
• Grade 3/4 differentiation syndrome in 8%; fatalities in 1%
• Hepatotoxicity occurred in 23% of patients; grade 3/4 in 13%
• One reported death from liver injury when combined with azacitidine

CLEVELAND, Jan. 15, 2026 /PRNewswire/ -- KeyCorp (NYSE: KEY) announced today that its Board of Directors declared the following dividends for the first quarter of 2026:

• A cash dividend of $0.205 per share on the corporation's outstanding common shares (NYSE: KEY). The dividend is payable on March 13, 2026, to holders of record of such Common Shares as of the close of business on March 3, 2026;
• A dividend of $312.50 per share (equivalent to $12.50 per depositary share (CUSIP #493267AK4)) on the corporation's outstanding Fixed-to-Floating Rate Perpetual Non-Cumulative Preferred Stock, Series D (CUSIP #493267603), payable on March 16, 2026 to holders of record as of the close of business on March 2, 2026, for the period commencing on (and including) December 15, 2025 to (but excluding) March 15, 2026;
• A dividend of $15.3125 per share (equivalent to $.382813 per depositary share (NYSE: KEY.I)) on the corporation's outstanding Fixed-to-Floating Rate Perpetual Non-Cumulative Preferred Stock, Series E (CUSIP #493267801), payable on March 16, 2026 to holders of record as of the close of business on March 2, 2026, for the period commencing on (and including) December 15, 2025 to (but excluding) March 15, 2026;
• A dividend of $14.1250 per share (equivalent to $.353125 per depositary share (NYSE: KEY.J)) on the corporation's outstanding Fixed Rate Perpetual Non-Cumulative Preferred Stock, Series F (CUSIP #493267884), payable on March 16, 2026 to holders of record as of the close of business on March 2, 2026, for the period commencing on (and including) December 15, 2025 to (but excluding) March 15, 2026;
• A dividend of $14.0625 per share (equivalent to $.351563 per depositary share (NYSE: KEY.K)) on the corporation's outstanding Fixed Rate Perpetual Non-Cumulative Preferred Stock, Series G (CUSIP #493267850), payable on March 16, 2026 to holders of record as of the close of business on March 2, 2026, for the period commencing on (and including) December 15, 2025 to (but excluding) March 15, 2026; and
• A dividend of $15.50 per share (equivalent to $.3875 per depositary share (NYSE: KEY.L)) on the corporation's outstanding Fixed Rate Reset Perpetual Non-Cumulative Preferred Stock, Series H (CUSIP #493267835), payable on March 16, 2026 to holders of record as of the close of business on March 2, 2026, for the period commencing on (and including) December 15, 2025 to (but excluding) March 15, 2026.

In addition, the Board of Directors has determined that the KeyCorp 2026 Annual Meeting of Shareholders will be held on Thursday, May 14, 2026.

About KeyCorp

KeyCorp's roots trace back more than 200 years to Albany, New York. Headquartered in Cleveland, Ohio, Key is one of the nation's largest bank-based financial services companies, with assets of approximately $187 billion at September 30, 2025.

Key provides deposit, lending, cash management, and investment services to individuals and businesses in 15 states under the name KeyBank National Association through a network of approximately 950 branches and approximately 1,200 ATMs. Key also provides a broad range of sophisticated corporate and investment banking products, such as merger and acquisition advice, public and private debt and equity, syndications and derivatives to middle market companies in selected industries throughout the United States under the KeyBanc Capital Markets trade name. For more information, visit https://www.key.com/. KeyBank Member FDIC.

 

FAQ

What did Rigel (RIGL) announce on January 15, 2026 about REZLIDHIA?

Rigel announced first patient enrollment in a Phase 1b/2 MD Anderson trial of decitabine + venetoclax plus REZLIDHIA for mIDH1 AML.

How many patients will the Phase 2 portion of the RIGL/MD Anderson trial include?

The Phase 2 will enroll 60 patients, split as 30 newly diagnosed and 30 relapsed/refractory mIDH1 AML patients.

What safety risks for REZLIDHIA were highlighted in the RIGL announcement?

Key risks include differentiation syndrome (16% incidence; grade 3/4 8%; fatalities 1%) and hepatotoxicity (23%; grade 3/4 13%).

Is REZLIDHIA approved for use in AML patients?

Yes; REZLIDHIA is indicated for adult patients with relapsed or refractory AML with a susceptible IDH1 mutation as detected by an FDA‑approved test.

What are the trial goals for the RIGL/MD Anderson study of REZLIDHIA?

Phase 1b will determine safety, tolerability, and recommended Phase 2 dose; Phase 2 will assess the complete remission rate in the two cohorts.

How might the trial timing affect RIGL clinical progress in 2026?

Enrollment milestone (first patient) starts the trial timeline; Phase 2 size and design set the near‑term clinical readout scope but no readout dates were provided.